Alosetron clinical trials
How each study uses alosetron is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 9 Feb 2000 · LOTRONEX · NDA 021107 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- alosetron
- 3
Studies by the year they started
4 studies that test it; most in 2003 (3)
| Year | Studies |
|---|---|
| 2003 | 3 |
| 2006 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of 5-HT3 antagonists source
Studies
Open first, then newest update. How each study uses alosetron is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)CompletedPhase 2GlaxoSmithKlineNCT01855711Written as GR68755 (Alosetron hydrochloride) 1 mg tablet
- Study to Assess the Effect Of Alosetron On Mucosal Blood FlowCompletedPhase 4GlaxoSmithKlineNCT00370032Written as alosetron
- Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional TherapyCompletedPhase 3GlaxoSmithKlineNCT00067457Written as alosetron
- Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional TherapyCompletedPhase 3GlaxoSmithKlineNCT00067561Written as Alosetron
Codes
What other systems call alosetron · ClinicalTrials.gg INT003819
- MeSH (NLM) C090840alosetronConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 13Z9HTH115ALOSETRONConfirmed FDA, NLM, Wikidata
- RxNorm 85248Confirmed FDA, Wikidata
- Wikidata Q416463alosetronConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73100AlosetronOne source FDA
- DrugBank DB00969One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C090840 | alosetron | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 13Z9HTH115 | ALOSETRON | Confirmed FDA, NLM, Wikidata |
| RxNorm | 85248 | — | Confirmed FDA, Wikidata |
| Wikidata | Q416463 | alosetron | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73100 | Alosetron | One source FDA |
| DrugBank | DB00969 | — | One source Wikidata |
Also registered as alosetron hydrochloride (UNII 2F5R1A46YW · RxNorm 85247).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.